Telmisartan Teva Pharma

RSS

telmisartan

Authorised
This medicine is authorised for use in the European Union.

Overview

This is a summary of the European public assessment report (EPAR) for Telmisartan Teva Pharma. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Telmisartan Teva Pharma.

This EPAR was last updated on 07/11/2019

Authorisation details

Product details
Name
Telmisartan Teva Pharma
Agency product number
EMEA/H/C/002511
Active substance
telmisartan
International non-proprietary name (INN) or common name
telmisartan
Therapeutic area (MeSH)
Hypertension
Anatomical therapeutic chemical (ATC) code
C09CA07
GenericGeneric

This is a generic medicine, which is developed to be the same as a medicine that has already been authorised, called the reference medicine. A generic medicine contains the same active substance(s) as the reference medicine, and is used at the same dose(s) to treat the same disease(s). For more information, see Generic and hybrid medicines.

Publication details
Marketing-authorisation holder
Teva B.V.
Revision
8
Date of issue of marketing authorisation valid throughout the European Union
03/10/2011
Contact address

Swensweg 5
2031GA Haarlem
The Netherlands

Product information

25/07/2019 Telmisartan Teva Pharma - EMEA/H/C/002511 - IB/0020

Contents

Please note that the size of the above document can exceed 50 pages.

You are therefore advised to be selective about which sections or pages you wish to print.

Pharmacotherapeutic group

Agents acting on the renin angiotensin system

Therapeutic indication

Treatment of essential hypertension in adults.

Assessment history

Changes since initial authorisation of medicine

How useful was this page?

Add your rating